Similarly to the function of PVT1, the lncRNA ANRIL, was described to exert a guiding function for PRC1 and PRC2 DNA binding in MM and was demonstrated to promote resistance to conventional therapies such as bortezomib by guiding PRC2 to promote gene silencing of the tumour suppressor gene PTEN. High expression of ANRIL has been associated with poor overall survival in MM (47) (Table 1). Here, CDKN2B-AS1 is linked to Miyoshi myopathy.